Pfizer's Buying Streak Continues

Its latest purchases include Medivation, the cancer drug company for US$14bn and AstraZeneca's antibiotics business for US$725 million.

Pfizer has not had it all its own way though. It had two failed attempts at major acquisitions in the last two years, firstly for the whole of AstraZeneca in 2014 and then with Allergan this year.

The sale by AstraZeneca is not a surprise, as it looks to sell off less profitable areas in order to focus on research. This is shown most recently by the sale of its anaesthetics business to Aspen Phamacare Holdings a number of months ago.

Whatever will Pfizer buy next?

For more information, please contact a member of our Pharmaceuricals and Life Sciences team, or complete the form below.